TMCI icon

Treace Medical Concepts

9.74 USD
-0.26
2.60%
Updated Feb 12, 11:44 AM EST
1 day
-2.60%
5 days
-7.85%
1 month
16.51%
3 months
21.14%
6 months
71.18%
Year to date
23.76%
1 year
-38.59%
5 years
-61.85%
10 years
-61.85%
 

About: Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers, and hospitals.

Employees: 227

0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

36% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 22

5% more funds holding

Funds holding: 126 [Q2] → 132 (+6) [Q3]

7% less call options, than puts

Call options by funds: $2.56M | Put options by funds: $2.74M

4.05% less ownership

Funds ownership: 69.2% [Q2] → 65.14% (-4.05%) [Q3]

18% less capital invested

Capital invested by funds: $285M [Q2] → $235M (-$50.5M) [Q3]

31% less repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 49

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$8
18%
downside
Avg. target
$10.30
6%
upside
High target
$14.50
49%
upside

3 analyst ratings

positive
33%
neutral
67%
negative
0%
Lake Street
Ben Haynor
43% 1-year accuracy
3 / 7 met price target
49%upside
$14.50
Buy
Initiated
31 Dec 2024
Truist Securities
Richard Newitter
81% 1-year accuracy
34 / 42 met price target
14%downside
$8.40
Hold
Maintained
18 Dec 2024
JP Morgan
Lilia-Celine Lozada
50% 1-year accuracy
1 / 2 met price target
18%downside
$8
Neutral
Assumed
17 Dec 2024

Financial journalist opinion

Based on 38 articles about TMCI published over the past 30 days

Neutral
Accesswire
1 day ago
The Schall Law Firm Invites Investors With Losses In Treace Medical Concepts, Inc. To Join A Securities Fraud Investigation
LOS ANGELES, CA / ACCESS Newswire / February 11, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Invites Investors With Losses In Treace Medical Concepts, Inc. To Join A Securities Fraud Investigation
Neutral
Accesswire
2 days ago
Treace Medical Concepts, Inc. Is Being Investigated For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESS Newswire / February 10, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Treace Medical Concepts, Inc. Is Being Investigated For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm
Neutral
Accesswire
3 days ago
The Schall Law Firm Invites Investors With Losses In Treace Medical Concepts, Inc. To Join A Securities Fraud Investigation
LOS ANGELES, CA / ACCESS Newswire / February 9, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Invites Investors With Losses In Treace Medical Concepts, Inc. To Join A Securities Fraud Investigation
Neutral
Accesswire
4 days ago
Treace Medical Concepts, Inc. Is Being Investigated For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESS Newswire / February 8, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Treace Medical Concepts, Inc. Is Being Investigated For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm
Neutral
Accesswire
5 days ago
The Schall Law Firm Invites Investors With Losses In Treace Medical Concepts, Inc. To Join A Securities Fraud Investigation
LOS ANGELES, CA / ACCESS Newswire / February 7, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Invites Investors With Losses In Treace Medical Concepts, Inc. To Join A Securities Fraud Investigation
Neutral
GlobeNewsWire
5 days ago
Treace to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025
PONTE VEDRA, Fla., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that it will release financial results for the fourth quarter and full year of 2024 after the close of trading on Thursday, February 27, 2025. Company management will host a conference call to discuss financial results beginning at 4:30 pm ET.
Treace to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025
Neutral
Accesswire
6 days ago
Treace Medical Concepts, Inc. Is Being Investigated For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESS Newswire / February 6, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Treace Medical Concepts, Inc. Is Being Investigated For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm
Neutral
Accesswire
1 week ago
The Schall Law Firm Invites Investors With Losses In Treace Medical Concepts, Inc. To Join A Securities Fraud Investigation
LOS ANGELES, CA / ACCESS Newswire / February 5, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Invites Investors With Losses In Treace Medical Concepts, Inc. To Join A Securities Fraud Investigation
Neutral
Accesswire
1 week ago
Treace Medical Concepts, Inc. Is Being Investigated For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm
LOS ANGELES, CA / ACCESS Newswire / February 3, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Treace Medical Concepts, Inc. Is Being Investigated For Securities Law Violations And Shareholders With Losses Are Urged To Contact The Schall Law Firm
Neutral
Accesswire
1 week ago
The Schall Law Firm Invites Investors With Losses To Join An Investigation Into Treace Medical Concepts, Inc. For Securities Fraud
LOS ANGELES, CA / ACCESS Newswire / February 2, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Treace Medical Concepts, Inc. ("Treace" or "the Company") (NASDAQ:TMCI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
The Schall Law Firm Invites Investors With Losses To Join An Investigation Into Treace Medical Concepts, Inc. For Securities Fraud
Charts implemented using Lightweight Charts™